Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

408 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oil blotting paper for formalin fixation increases endoscopic ultrasound-guided tissue acquisition-collected sample volumes on glass slides.
Yamai T, Ikezawa K, Seiki Y, Watsuji K, Kawamoto Y, Hirao T, Daiku K, Maeda S, Urabe M, Kai Y, Takada R, Mukai K, Nakabori T, Uehara H, Tsuzaki S, Ryu A, Tanada S, Nagata S, Ohkawa K. Yamai T, et al. Among authors: ohkawa k. Cancer Med. 2024 May;13(9):e7189. doi: 10.1002/cam4.7189. Cancer Med. 2024. PMID: 38706442 Free PMC article.
Safety and Feasibility of Combining On-Demand Selective Locoregional Treatment with First-Line Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma.
Nakabori T, Higashi S, Abe Y, Mukai K, Ikawa T, Konishi K, Maeda N, Nakanishi K, Hasegawa S, Wada H, Ohkawa K. Nakabori T, et al. Among authors: ohkawa k. Curr Oncol. 2024 Mar 15;31(3):1543-1555. doi: 10.3390/curroncol31030117. Curr Oncol. 2024. PMID: 38534950 Free PMC article.
Duodenal Papillary Metastasis of Lung Cancer with Bleeding Controlled by Endoscopic Treatment and Systemic Osimertinib Therapy: Case Report.
Hirata T, Kawaguchi S, Akamatsu T, Inagawa A, Hikichi T, Ohkawa K, Asahara K, Satoh T, Endo S, Suzuki M, Ohno K. Hirata T, et al. Among authors: ohkawa k. Case Rep Gastroenterol. 2024 Mar 12;18(1):122-128. doi: 10.1159/000537778. eCollection 2024 Jan-Dec. Case Rep Gastroenterol. 2024. PMID: 38476646 Free PMC article.
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, Yarchoan M, De Toni EN, Furuse J, Kang YK, Galle PR, Rimassa L, Heurgué A, Tam VC, Van Dao T, Thungappa SC, Breder V, Ostapenko Y, Reig M, Makowsky M, Paskow MJ, Gupta C, Kurland JF, Negro A, Abou-Alfa GK; HIMALAYA investigators. Sangro B, et al. Ann Oncol. 2024 May;35(5):448-457. doi: 10.1016/j.annonc.2024.02.005. Epub 2024 Feb 19. Ann Oncol. 2024. PMID: 38382875 Free article. Clinical Trial.
Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study.
Kai M, Hikita H, Kazuki M, Tahata Y, Shinkai K, Doi A, Ohkawa K, Miyazaki M, Ishida H, Matsumoto K, Nozaki Y, Yakushijin T, Sakamori R, Kaneko A, Iio S, Nawa T, Kakita N, Morishita N, Hiramatsu N, Usui T, Imanaka K, Doi Y, Sakakibara M, Yoshida Y, Oze T, Kodama T, Tatsumi T, Takehara T. Kai M, et al. Among authors: ohkawa k. PLoS One. 2024 Jan 2;19(1):e0294590. doi: 10.1371/journal.pone.0294590. eCollection 2024. PLoS One. 2024. PMID: 38165900 Free PMC article.
408 results